Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182874 | 0.87 | NAAA (0.48) | NAAA | |
| SCHEMBL577650 | 0.73 | MAPT (0.45) | — | |
| SCHEMBL577651 | 0.71 | MAPT (0.44) | — | |
| SCHEMBL17203079 | 0.71 | GSK3B (0.52) | HDAC1HDAC6HDAC3 | |
| SCHEMBL8928677 | 0.69 | KMT2A (0.39) | — | |
| SCHEMBL3203700 | 0.69 | PKM (0.47) | — | |
| SCHEMBL3191091 | 0.68 | PTGS2 (0.51) | — | |
| SCHEMBL29358739 | 0.68 | HDAC1 (1.00) | HDAC1HDAC8HDAC11HDAC6HDAC3 | |
| SCHEMBL8390586 | 0.66 | HDAC3 (0.77) | HDAC1HDAC8HDAC11HDAC6HDAC3 | |
| SCHEMBL9826082 | 0.66 | HSD17B10 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | CYP3A7, DHCR7, CYP2A7 | HDAC1 2484/4885HDAC8 1340/4885HDAC11 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.